Abstract
BackgroundNNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to IL-20 and neutralises its activity. The primary endpoint in this multicentre, randomised, double-blind, placebo-controlled, parallel group trial...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have